Other Events ·
Indivior stockholders approve share issuance for merger under Nasdaq Rule 5635
INDVSupernus, Inc.
At a special meeting on October 15, 2026, Indivior Pharmaceuticals stockholders approved the issuance of shares in connection with a pending merger agreement. The proposal received 85,455,705 votes in favor against 5,563,744, representing approximately 93.6% of votes cast by the 77.27% quorum present. This approval is required to comply with Nasdaq Rule 5635 regarding share issuance for business combinations. Indivior Pharmaceuticals operates in the pharmaceutical industry, focusing on addiction treatment therapies.